NCT02145507View on ClinicalTrials.gov

Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution

PHASE1CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2015

Conditions
Blood Donors
Interventions
DRUG

SOLX (Investigational)

SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.

DRUG

AS-3 (Control)

AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit

Trial Locations (2)

23507

American Red Cross Mid-Atlantic Region Blood Services, Norfolk

45267

Hoxworth Blood Center, Cincinnati

Sponsors
All Listed Sponsors
lead

Haemonetics Corporation

INDUSTRY